RNTX director granted 17,500 stock options at $1.55 – Form 4

Rein Therapeutics, Inc. (RNTX) – Form 4 insider filing Director William C. Fairey reported the grant of 17,500 non-qualified stock options on 07/23/2025.

Rhea-AI Filing Summary

Rein Therapeutics, Inc. (RNTX) – Form 4 insider filing

Director William C. Fairey reported the grant of 17,500 non-qualified stock options on 07/23/2025. The options carry a $1.55 exercise price and will vest in full on the earlier of 07/23/2026 or the company’s 2026 annual shareholder meeting, provided the director remains in service. The options expire on 07/22/2035. No common shares were bought or sold and the filing shows direct ownership of the new derivative position. This appears to be routine board compensation and does not alter the company’s capital structure or provide guidance on operating performance.

Insights

Securities Analyst

TL;DR: Routine director option grant; neutral impact on valuation.

The 17,500-share option award aligns Fairey’s incentives with shareholders but is immaterial to Rein Therapeutics’ float or earnings. With a 10-year term and $1.55 strike, value depends on future share appreciation; no immediate cash outflow or dilution occurs until exercise. No share sales signal insider confidence, yet the small size (<0.1% potential dilution) limits market impact. Overall, the filing is administrative and does not shift the investment thesis.

Insider Trade Summary

Grant/Award: 17,500 shares

Grant/Award 1 txn

Insider Fairey William

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	17,500	$0.00	$0.00

Holdings After Transaction: Stock Option (right to buy) — 17,500 contracts (Direct)

Footnotes (1)

1. F1. This option was granted on July 23, 2025. The shares underlying the option are scheduled to vest in full on the earlier of (i) July 23, 2026 or (ii) the date of the Issuer's 2026 Annual Meeting of Stockholders, subject to continued service.

FAQ

What did RNTX director William Fairey report on the Form 4?

He received 17,500 stock options with a $1.55 exercise price; no shares were bought or sold.

When will the granted options to William Fairey vest?

They vest in full on the earlier of July 23 2026 or Rein Therapeutics’ 2026 annual meeting.

What is the expiration date of the RNTX options granted?

The options expire on July 22 2035.

Did the Form 4 disclose any sales of Rein Therapeutics stock?

No. The filing only reports an acquisition of options; there were no share dispositions.

How many derivative securities does Fairey own after this transaction?

He now beneficially owns 17,500 stock options directly.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 07/23/2025 - 07:37 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person^*

Fairey William

(Last) (First) (Middle)

C/O REIN THERAPEUTICS, INC.

12407 N. MOPAC EXPY. SUITE 250 #390

(Street)

AUSTIN TX 78758

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Rein Therapeutics, Inc. [ RNTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
07/23/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$1.55	07/23/2025		A		17,500		(1)	07/22/2035	Common Stock	17,500	$0.00	17,500	D

Explanation of Responses:

1. This option was granted on July 23, 2025. The shares underlying the option are scheduled to vest in full on the earlier of (i) July 23, 2026 or (ii) the date of the Issuer's 2026 Annual Meeting of Stockholders, subject to continued service.

	/s/ Brian Windsor, attorney-in-fact for William C. Fairey	07/23/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.